Targeting the Residual Leukemia Cells after Chemotherapy
- PMID: 30205040
- DOI: 10.1016/j.ccell.2018.08.012
Targeting the Residual Leukemia Cells after Chemotherapy
Abstract
One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML recurrence.
Copyright © 2018 Elsevier Inc. All rights reserved.
Comment on
-
Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence.Cancer Cell. 2018 Sep 10;34(3):483-498.e5. doi: 10.1016/j.ccell.2018.08.007. Cancer Cell. 2018. PMID: 30205048
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical